New agents and interventions are paving the way for revised modalities in the evaluation and management of patients with atrial fibrillation--the most common arrhythmia, which affects an estimated 2.2 million people in the US alone. Join Drs Alpert and Delascio Lopes for a review of the latest findings, including promising new antithrombotic and anticoagulation agents, stroke prevention, the ongoing rhythm-vs-rate-control debate, ATHENA, RE-LY, and CABANA, as well as the CHADS2 score.